JO3330B1 - الأجسام المضادة cgrp - Google Patents

الأجسام المضادة cgrp

Info

Publication number
JO3330B1
JO3330B1 JOP/2011/0177A JOP20110177A JO3330B1 JO 3330 B1 JO3330 B1 JO 3330B1 JO P20110177 A JOP20110177 A JO P20110177A JO 3330 B1 JO3330 B1 JO 3330B1
Authority
JO
Jordan
Prior art keywords
cgrp
antibodies
cgrp antibodies
antigen
binding fragment
Prior art date
Application number
JOP/2011/0177A
Other languages
English (en)
Inventor
Allan Barrett
Jan Benschop Robert
James Darling Ryan
Geoffrey Chambers Mark
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3330B1 publication Critical patent/JO3330B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يقدم الاختراع الحالي أجسام مضادة بشرية معدلة وراثيًا للببتيد المرتبط بجين كالسيتونين (CGRP) أو شظية الارتباط بمولد الضد منها. بالإضافة إلى ذلك، يقدم الاختراع الحالي استخدام الأجسام المضادة البشرية المعدلة وراثيًا للببتيد المرتبط بجين كالسيتونين (CGRP) أو شظية الارتباط بمولد الضد منها وذلك لعلاج ألم الالتهاب العظمي المفصلي.
JOP/2011/0177A 2010-06-10 2011-05-31 الأجسام المضادة cgrp JO3330B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35332310P 2010-06-10 2010-06-10

Publications (1)

Publication Number Publication Date
JO3330B1 true JO3330B1 (ar) 2019-03-13

Family

ID=45096388

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0177A JO3330B1 (ar) 2010-06-10 2011-05-31 الأجسام المضادة cgrp

Country Status (33)

Country Link
US (3) US9073991B2 (ar)
EP (2) EP2579894B1 (ar)
JP (2) JP6021806B2 (ar)
KR (1) KR101489566B1 (ar)
CN (2) CN104292332B (ar)
AR (1) AR081434A1 (ar)
AU (1) AU2011265050B2 (ar)
BR (1) BR112012031501B1 (ar)
CA (1) CA2802102C (ar)
CY (2) CY1119789T1 (ar)
DK (1) DK2579894T3 (ar)
EA (1) EA022931B1 (ar)
ES (2) ES2656000T3 (ar)
HR (1) HRP20171992T1 (ar)
HU (2) HUE038135T2 (ar)
IL (2) IL222885B (ar)
JO (1) JO3330B1 (ar)
LT (2) LT2579894T (ar)
LU (1) LUC00112I2 (ar)
ME (1) ME02862B (ar)
MX (2) MX340999B (ar)
NL (1) NL300979I2 (ar)
NO (2) NO2579894T3 (ar)
NZ (1) NZ603607A (ar)
PL (1) PL2579894T3 (ar)
PT (1) PT2579894T (ar)
RS (1) RS56638B1 (ar)
SG (1) SG185648A1 (ar)
SI (1) SI2579894T1 (ar)
TW (1) TWI423818B (ar)
UA (1) UA109658C2 (ar)
WO (1) WO2011156324A1 (ar)
ZA (1) ZA201208996B (ar)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3069731A1 (en) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
CN102740884A (zh) 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
TWI705825B (zh) 2011-05-20 2020-10-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）或抗降血鈣素基因相關胜肽受器（ａｎｔｉ－ｃｇｒｐ－ｒ）抗體或抗體片段治療或預防慢性及急性型腹瀉之用途
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PE20141787A1 (es) 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN107108715A (zh) 2014-10-24 2017-08-29 默沙东公司 胰高血糖素和glp‑1受体的共激动剂
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
TWI799849B (zh) 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
BR112018007214A2 (pt) * 2015-10-30 2018-10-16 Lilly Co Eli anticorpos biespecíficos anti-cgrp/anti-il-23 e usos destes
CN105483091A (zh) * 2015-12-29 2016-04-13 天津三箭生物技术股份有限公司 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
EA201891196A1 (ru) * 2016-01-28 2018-12-28 Эли Лилли Энд Компани Cgrp-антитела и их применение
US11492386B2 (en) 2016-02-01 2022-11-08 Eli Lilly And Company Parathyroid hormone-anti-RANKL antibody fusion compounds
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
EA201990548A1 (ru) 2016-09-23 2019-09-30 Тева Фармасьютикалз Интернэшнл Гмбх Лечение кластерной головной боли
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
RU2770066C2 (ru) 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
AR111845A1 (es) 2017-05-03 2019-08-28 Lilly Co Eli Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
JP2020525445A (ja) 2017-06-21 2020-08-27 セファロン・インコーポレイテッドＣｅｐｈａｌｏｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ カチオン交換クロマトグラフィーの洗浄緩衝液
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
SG11202006610YA (en) 2018-01-12 2020-08-28 Amgen Inc Pac1 antibodies and uses thereof
WO2019231800A1 (en) 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
US20210340230A1 (en) 2018-08-22 2021-11-04 Eli Lilly And Company Anti-CGRP Antibodies For Treatment-Resistant Patients
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies
EP3744400A1 (en) * 2019-05-28 2020-12-02 Etablissement Français du Sang Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml)
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
CA3077973A1 (en) 2020-04-06 2021-10-06 H. Lundbeck A/S Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan
EP4570913A1 (en) * 2022-08-11 2025-06-18 Shanghai Junshi Biosciences Co., Ltd. Anti-cgrp antibody and use
CN118271438B (zh) * 2024-05-27 2024-08-30 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途
CN119320450B (zh) * 2024-12-13 2025-07-25 中国人民解放军军事科学院军事医学研究院 针对降钙素基因相关肽的抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
JP4976376B2 (ja) 2005-04-08 2012-07-18 メディミューン，エルエルシー 哺乳動物メタニューモウイルスに対する抗体
EP3069731A1 (en) * 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
WO2009109908A1 (en) * 2008-03-04 2009-09-11 Pfizer Limited Methods of treating inflammatory pain
RU2522493C2 (ru) * 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo

Also Published As

Publication number Publication date
JP6466883B2 (ja) 2019-02-06
US20170073403A1 (en) 2017-03-16
CA2802102A1 (en) 2011-12-15
EA022931B1 (ru) 2016-03-31
IL222885A0 (en) 2012-12-31
SG185648A1 (en) 2012-12-28
BR112012031501A2 (pt) 2016-10-25
MX363209B (es) 2019-03-14
NL300979I1 (nl) 2019-04-17
EP3318272B1 (en) 2022-08-10
EP3318272A1 (en) 2018-05-09
NL300979I2 (nl) 2019-07-11
WO2011156324A1 (en) 2011-12-15
CY2019017I2 (el) 2020-05-29
UA109658C2 (xx) 2015-09-25
KR101489566B1 (ko) 2015-02-03
MX340999B (es) 2016-08-03
ES2656000T3 (es) 2018-02-22
TWI423818B (zh) 2014-01-21
ZA201208996B (en) 2014-05-28
CN102946905B (zh) 2014-10-15
HRP20171992T1 (hr) 2018-02-09
CY2019017I1 (el) 2020-05-29
EA201270769A1 (ru) 2013-04-30
US9505838B2 (en) 2016-11-29
NO2019017I1 (no) 2019-04-05
LTC2579894I2 (lt) 2020-03-25
JP2013532143A (ja) 2013-08-15
EP2579894B1 (en) 2017-11-22
AU2011265050A1 (en) 2012-11-08
US20110305711A1 (en) 2011-12-15
US20150259415A1 (en) 2015-09-17
HUE038135T2 (hu) 2018-09-28
EP2579894A1 (en) 2013-04-17
AU2011265050B2 (en) 2013-06-27
AR081434A1 (es) 2012-08-29
CY1119789T1 (el) 2018-06-27
TW201210618A (en) 2012-03-16
NO2579894T3 (ar) 2018-04-21
LT2579894T (lt) 2018-02-26
IL242409B (en) 2020-07-30
PL2579894T3 (pl) 2018-04-30
KR20130034024A (ko) 2013-04-04
DK2579894T3 (en) 2018-01-15
JP2017014203A (ja) 2017-01-19
MX2012014480A (es) 2013-02-07
US9073991B2 (en) 2015-07-07
NZ603607A (en) 2014-09-26
PT2579894T (pt) 2018-02-06
SI2579894T1 (en) 2018-01-31
HUS1900020I1 (hu) 2019-05-28
ME02862B (me) 2018-04-20
IL222885B (en) 2019-09-26
EP2579894A4 (en) 2013-12-04
BR112012031501B1 (pt) 2020-02-11
LTPA2019011I1 (lt) 2019-05-10
RS56638B1 (sr) 2018-03-30
CN104292332B (zh) 2019-11-01
LUC00112I2 (ar) 2019-12-27
CN104292332A (zh) 2015-01-21
CA2802102C (en) 2016-07-26
HK1203211A1 (en) 2015-10-23
ES2930321T3 (es) 2022-12-09
CN102946905A (zh) 2013-02-27
LUC00112I1 (ar) 2019-04-10
JP6021806B2 (ja) 2016-11-09

Similar Documents

Publication Publication Date Title
JO3330B1 (ar) الأجسام المضادة cgrp
PH12013500277A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
MX355543B (es) Macrociclos peptidomiméticos.
EA201290557A1 (ru) Пептидный аналог оксинтомодулина
SG194701A1 (en) Anti-cd40 antibodies and methods of use
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
MX350234B (es) Compuestos de enlace especificos de bacterias gram-positivas.
EA201490039A1 (ru) Химерные и гибридные полипептиды фактора viii и способы их применения
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
NZ626242A (en) Anti-asic1 antibodies and uses thereof
MX2012002464A (es) El uso de anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de la calcitonina para tratar dolor visceral.
NZ607588A (en) Antibodies against human TWEAK and uses thereof
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
PH12015501360A1 (en) Bmp-6 antibodies
PH12013501205A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2013007995A (es) Peptidos derivados de lactoferrina humana y su uso.
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
HK1198135A1 (en) Prevention and treatment of pain using antibodies to lysophosphatidic acid
EP2552462A4 (en) CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS
GB201103780D0 (en) Treatment for ige-mediated disease
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.